https://sciencelink.com/noticias/tivozanib-incrementa-la-slp-en-comparacion-con-sunitinib-en-pacientes-con-cancer-renal-avanzado-altamente-refractario/
Tivozanib incrementa la SLP en comparación con sorafenib en pacientes con cáncer renal avanzado...
El estudio TIVO-3, fase III, aleatorio, controlado, multicéntrico, abierto comparando tivozanib versus sorafenib en 351 pacientes con cáncer renal avanzado...
tivozanibincrementaslpconsorafenib
https://pazopanib.net/index.php?g=Wap&m=Article&a=detail&id=147
Tivozanib (AV-951): Precision-Driven VEGFR Inhibitor for ... – Inhibitor Research Hub
Tivozanib (AV-951): Precision-Driven VEGFR Inhibitor for Advanced Cancer Research Introduction: The Evolving Role of VEGFR Inhibition in Oncology Th
vegfr inhibitorresearch hubtivozanibprecisiondriven
https://digitalcommons.library.tmc.edu/uthgsbs_docs/1719/
"Efficacy, Safety, and Tolerability of Tivozanib in Heavily Pretreated " by Andrew C Johns, Matthew...
BACKGROUND: Tivozanib has been approved as a third-line or later therapy for advanced renal cell carcinoma based on the TIVO-3 trial, which was conducted...
by andrewefficacysafetytolerabilitytivozanib